针对 KSHV 相关疾病的免疫疗法。
Immunotherapy for KSHV-associated diseases.
机构信息
HIV & AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
HIV & AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
出版信息
Curr Opin Virol. 2022 Aug;55:101249. doi: 10.1016/j.coviro.2022.101249. Epub 2022 Jul 5.
Abstract
Kaposi sarcoma herpesvirus (KSHV)-associated diseases (Kaposi sarcoma, multicentric Castleman disease, primary effusion lymphoma, and KSHV inflammatory cytokine syndrome) are associated with immune suppression and dysregulation and loss of KSHV-specific immunity. These diseases are most frequent in people living with HIV as well as those with primary or iatrogenic immune deficiencies. KSHV itself can modulate the immune system via viral homologs of host cytokines or downregulation of immune-surface markers altering host immune surveillance. These factors make KSHV-associated diseases prime targets for immunotherapy approaches. Several agents have been studied or are under investigation in KSHV-associated diseases, including monoclonal antibodies, immunomodulatory agents, and therapeutic cytokines. Here, we review the role of immunotherapies in KSHV-associated diseases.
摘要
卡波西肉瘤疱疹病毒（KSHV）相关疾病（卡波西肉瘤、多中心性 Castleman 病、原发性渗出性淋巴瘤和 KSHV 炎症细胞因子综合征）与免疫抑制和失调以及丧失 KSHV 特异性免疫有关。这些疾病在 HIV 感染者以及原发性或医源性免疫缺陷者中最为常见。KSHV 本身可以通过病毒宿主细胞因子的同源物或改变宿主免疫监视的免疫表面标志物的下调来调节免疫系统。这些因素使得 KSHV 相关疾病成为免疫治疗方法的主要目标。已经研究或正在研究几种药物治疗 KSHV 相关疾病，包括单克隆抗体、免疫调节剂和治疗性细胞因子。在这里，我们综述了免疫疗法在 KSHV 相关疾病中的作用。
相似文献
1
Immunotherapy for KSHV-associated diseases.针对 KSHV 相关疾病的免疫疗法。
Curr Opin Virol. 2022 Aug;55:101249. doi: 10.1016/j.coviro.2022.101249. Epub 2022 Jul 5.
2
Kaposi sarcoma herpesvirus-associated cancers and related diseases.卡波西肉瘤疱疹病毒相关癌症及相关疾病
Curr Opin HIV AIDS. 2017 Jan;12(1):47-56. doi: 10.1097/COH.0000000000000330.
3
Clinical management of Kaposi sarcoma herpesvirus-associated diseases: an update on disease manifestations and treatment strategies.卡波西肉瘤疱疹病毒相关疾病的临床管理：疾病表现和治疗策略的更新。
Expert Rev Anti Infect Ther. 2023 Jul-Dec;21(9):929-941. doi: 10.1080/14787210.2023.2247161. Epub 2023 Aug 15.
4
Kaposi sarcoma-associated herpesvirus complement control protein (KCP) and glycoprotein K8.1 are not required for viral infection or .卡波西肉瘤相关疱疹病毒补体控制蛋白（KCP）和糖蛋白K8.1对于病毒感染并非必需的，或者…… （原文此处不完整）
J Virol. 2024 Jun 13;98(6):e0057624. doi: 10.1128/jvi.00576-24. Epub 2024 May 20.
5
Unraveling the Kaposi Sarcoma-Associated Herpesvirus (KSHV) Lifecycle: An Overview of Latency, Lytic Replication, and KSHV-Associated Diseases.解析卡波西肉瘤相关疱疹病毒（KSHV）的生命周期：潜伏、裂解复制及KSHV相关疾病概述
Viruses. 2025 Jan 26;17(2):177. doi: 10.3390/v17020177.
6
Kaposi sarcoma-associated herpesvirus (KSHV): molecular biology and oncogenesis.卡波西肉瘤相关疱疹病毒（KSHV）：分子生物学与致癌机制。
Cancer Lett. 2010 Mar 28;289(2):140-50. doi: 10.1016/j.canlet.2009.07.004. Epub 2009 Aug 3.
7
Adaptive immune responses to Kaposi's sarcoma-associated herpesvirus.卡波氏肉瘤相关疱疹病毒的适应性免疫反应。
Curr Opin Immunol. 2022 Aug;77:102230. doi: 10.1016/j.coi.2022.102230. Epub 2022 Jul 8.
8
KSHV-associated multicentric Castleman disease: A tangle of different entities requiring multitarget treatment strategies.卡波西肉瘤相关多中心型 Castleman 病：一种需要多靶点治疗策略的复杂疾病实体。
Int J Cancer. 2015 Jul 15;137(2):251-61. doi: 10.1002/ijc.28923. Epub 2014 May 5.
9
18F-fluorodeoxyglucose Positron Emission Tomography in Kaposi Sarcoma Herpesvirus-Associated Multicentric Castleman Disease: Correlation With Activity, Severity, Inflammatory and Virologic Parameters.18F-氟脱氧葡萄糖正电子发射断层扫描在卡波西肉瘤相关多中心性Castleman病中的应用：与活动度、严重程度、炎症及病毒学参数的相关性
J Infect Dis. 2015 Oct 15;212(8):1250-60. doi: 10.1093/infdis/jiv204. Epub 2015 Mar 31.
10
An interleukin-6-related systemic inflammatory syndrome in patients co-infected with Kaposi sarcoma-associated herpesvirus and HIV but without Multicentric Castleman disease.卡波西肉瘤相关疱疹病毒和 HIV 合并感染但无多中心性 Castleman 病患者的白细胞介素 6 相关全身性炎症综合征。
Clin Infect Dis. 2010 Aug 1;51(3):350-8. doi: 10.1086/654798.
引用本文的文献
1
Oncogenic Mechanisms of Kaposi's Sarcoma-Associated Herpesvirus on Cell Metabolism and Cell Transformation.卡波西肉瘤相关疱疹病毒对细胞代谢和细胞转化的致癌机制
J Med Virol. 2025 Aug;97(8):e70565. doi: 10.1002/jmv.70565.
2
Phase I study of efineptakin alfa (NT-I7) for the treatment of Kaposi sarcoma.阿法依那西普（NT-I7）治疗卡波西肉瘤的I期研究。
J Immunother Cancer. 2025 Feb 6;13(2):e010291. doi: 10.1136/jitc-2024-010291.
3
Structure of the Kaposi's sarcoma-associated herpesvirus gB in post-fusion conformation.卡波西肉瘤相关疱疹病毒糖蛋白B融合后构象的结构
J Virol. 2025 Feb 25;99(2):e0153324. doi: 10.1128/jvi.01533-24. Epub 2025 Jan 17.
4
Primary Effusion Lymphoma Prognostic Score (PEL-PS): A Validated International Prognostic Score in HIV-Associated Primary Effusion Lymphoma.原发性渗出性淋巴瘤预后评分（PEL-PS）：一种经验证的HIV相关原发性渗出性淋巴瘤国际预后评分。
Am J Hematol. 2025 Mar;100(3):393-401. doi: 10.1002/ajh.27580. Epub 2025 Jan 15.
5
The 'Oma's of the Gammas-Cancerogenesis by γ-Herpesviruses.γ疱疹病毒引发的γ细胞癌变——“祖母”因素
Viruses. 2024 Dec 17;16(12):1928. doi: 10.3390/v16121928.
6
Hypoxic reactivation of Kaposi's sarcoma associated herpesvirus.卡波西肉瘤相关疱疹病毒的低氧再激活
Cell Insight. 2024 Sep 7;3(6):100200. doi: 10.1016/j.cellin.2024.100200. eCollection 2024 Dec.
7
Promising immunotherapeutic approaches for primary effusion lymphoma.原发性渗出性淋巴瘤有前景的免疫治疗方法。
Explor Target Antitumor Ther. 2024;5(3):699-713. doi: 10.37349/etat.2024.00242. Epub 2024 Jun 26.
8
Spurious Presentation of Pulmonary Kaposi Sarcoma as Unresolved Pneumonia Led to Fatal Outcome.肺血管肉瘤表现为未明确的肺炎，导致致命后果。
J Investig Med High Impact Case Rep. 2023 Jan-Dec;11:23247096231208996. doi: 10.1177/23247096231208996.
9
Clinical management of Kaposi sarcoma herpesvirus-associated diseases: an update on disease manifestations and treatment strategies.卡波西肉瘤疱疹病毒相关疾病的临床管理：疾病表现和治疗策略的更新。
Expert Rev Anti Infect Ther. 2023 Jul-Dec;21(9):929-941. doi: 10.1080/14787210.2023.2247161. Epub 2023 Aug 15.
10
Echinomycin as a promising therapeutic agent against KSHV-related malignancies.表鬼臼毒素作为一种有前途的治疗药物，可对抗与 KSHV 相关的恶性肿瘤。
J Hematol Oncol. 2023 May 4;16(1):48. doi: 10.1186/s13045-023-01441-5.
本文引用的文献
1
Safety, Activity, and Long-term Outcomes of Pomalidomide in the Treatment of Kaposi Sarcoma among Individuals with or without HIV Infection.泊马度胺治疗 HIV 感染者和非感染者卡波西肉瘤的安全性、疗效和长期结果。
Clin Cancer Res. 2022 Mar 1;28(5):840-850. doi: 10.1158/1078-0432.CCR-21-3364.
2
Efficacy and mechanism of the anti-CD38 monoclonal antibody Daratumumab against primary effusion lymphoma.抗 CD38 单克隆抗体达雷妥尤单抗治疗原发性渗出性淋巴瘤的疗效及机制。
Cancer Immunol Immunother. 2022 May;71(5):1017-1031. doi: 10.1007/s00262-021-03054-8. Epub 2021 Sep 20.
3
Characteristics and outcomes of KSHV-associated multicentric Castleman disease with or without other KSHV diseases.卡波西肉瘤相关多中心型 Castleman 病伴或不伴其他 KSHV 疾病的特征和结局。
Blood Adv. 2021 Mar 23;5(6):1660-1670. doi: 10.1182/bloodadvances.2020004058.
4
Use of pembrolizumab with or without pomalidomide in HIV-associated non-Hodgkin's lymphoma.帕博利珠单抗联合或不联合泊马度胺在HIV相关非霍奇金淋巴瘤中的应用。
J Immunother Cancer. 2021 Feb;9(2). doi: 10.1136/jitc-2020-002097.
5
Adoptive T-Cell Therapy for Epstein-Barr Virus-Related Lymphomas.采用过继性T细胞疗法治疗爱泼斯坦-巴尔病毒相关淋巴瘤。
J Clin Oncol. 2021 Feb 10;39(5):514-524. doi: 10.1200/JCO.20.01709. Epub 2021 Jan 12.
6
Cytokine-Targeted Therapeutics for KSHV-Associated Disease.针对 KSHV 相关疾病的细胞因子靶向治疗。
Viruses. 2020 Sep 28;12(10):1097. doi: 10.3390/v12101097.
7
Anti-PD-1 and Anti-PD-L1 Monoclonal Antibodies in People Living with HIV and Cancer.抗 PD-1 和抗 PD-L1 单克隆抗体在 HIV 感染者和癌症患者中的应用。
Curr HIV/AIDS Rep. 2020 Oct;17(5):547-556. doi: 10.1007/s11904-020-00525-y.
8
Tocilizumab in patients with symptomatic Kaposi sarcoma herpesvirus-associated multicentric Castleman disease.托珠单抗治疗有症状的卡波西肉瘤疱疹病毒相关多中心性Castleman病患者。
Blood. 2020 Jun 18;135(25):2316-2319. doi: 10.1182/blood.2019004602.
9
KSHV: Immune Modulation and Immunotherapy.卡波西肉瘤相关疱疹病毒：免疫调节与免疫治疗。
Front Immunol. 2020 Feb 7;10:3084. doi: 10.3389/fimmu.2019.03084. eCollection 2019.
10
Effect of daratumumab on normal plasma cells, polyclonal immunoglobulin levels, and vaccination responses in extensively pre-treated multiple myeloma patients.达雷妥尤单抗对接受过广泛预处理的多发性骨髓瘤患者正常浆细胞、多克隆免疫球蛋白水平及疫苗接种反应的影响。
Haematologica. 2020 Jun;105(6):e302-e306. doi: 10.3324/haematol.2019.231860. Epub 2019 Sep 26.
Zotero 插件